Skip to main content

Table 6 Rapamycin treated nude mice with Tsc2-/- tumors fail to gain weight

From: Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models

 

Weight at Start (g)

Weight at Necropsy (g)

Weight gain (g)

P value

Untreated

34.6 ± 1.1

37.8 ± 0.9

3.2 ± 0.9

*0.0388

    

-

    

-

Rapamycin treated

36.0 ± 0.6

35.6 ± 0.6

-0.4 ± 0.6

*NS

    

**NS

    

#NS

Other treatment

33.8 ± 0.6

36.8 ± 0.7

3.1 ± 0.4

*0.0024

    

**NS

    

#NS

  1. *Weight at start compared with weight at necropsy (within the same treatment group)
  2. **Weight at start compared to untreated at start
  3. #Weight at necropsy compared to untreated at necropsy
Back to article page

BMC Pharmacology

ISSN: 1471-2210